Fluicell (FLUI) Q2 2026 earnings summary

Executive summary

• Achieved the strongest revenue quarter in company history, with Q2 net sales up 934% year-over-year and five consecutive quarters of increasing net sales.

• Strategic progress with successful project milestones in diabetes and cancer collaborations, and strengthened board with new commercial expertise.

• AI integration implemented across all projects, enhancing screening solutions and data analysis.

Financial highlights

• Q2 2026 net sales: 7,277 KSEK (704 KSEK in Q2 2025), total operating income: 8,701 KSEK (3,541 KSEK).

• EBITDA for Q2: 2,314 KSEK (-2,734 KSEK), EBIT: 2,239 KSEK (-2,824 KSEK), net income: 2,260 KSEK (-2,887 KSEK).

• H1 2026 net sales: 13,372 KSEK (934 KSEK in H1 2025), EBITDA: 5,693 KSEK (-5,274 KSEK), EBIT: 5,531 KSEK (-5,468 KSEK), net income: 5,570 KSEK (-5,562 KSEK).

• EPS Q2: 1.65 SEK (-2.10 SEK), H1: 4.05 SEK (-4.05 SEK).

• Cash flow from operations Q2: -2,092 KSEK (-2,879 KSEK), H1: -1,844 KSEK (-6,672 KSEK).

Outlook and guidance

• Focus for the remainder of 2026 is on broadening revenue streams and strengthening liquidity, with commercialization of advanced cardiac tissue models as a key path.

• Management expects continued positive momentum, supported by new board expertise and ongoing innovation.

• Full-year 2026 result and cash flow forecasted between -1 MSEK and +1 MSEK.